“It is unknown to what degree aducanumab (Aduhelm) may help people with Down syndrome, as they were not included among the trial participants…” As the conversation around Biogen’s Aduhelm continues, one thing remains crystal clear: there is still much to learn about the drug. LuMind IDSC endorses this thoughtful statement from the National Task Group on Intellectual Disabilities and Dementia Practices, regarding issues related to use of Aduhelm by persons with Down syndrome.
